Diffuse Parenchymal Lung Disease in Later Childhood

Lauren E. Bradford; Eveline Y. Wu; Frederic B. Askin; Timothy J. Vece

doi:10.1016/B978-0-08-102723-3.00141-4

Diffuse Parenchymal Lung Disease in Later Childhood

Lauren E. Bradford, Eveline Y. Wu, Frederic B. Askin, Timothy J. Vece

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

Diffuse lung disease (DLD) refers to a heterogenous group of diseases that result in disordered gas exchange. The etiology of DLD in children aged 2–18years old is broad and is most frequently secondary to infectious or post-infectious processes, systemic disease, or immune dysfunction. Advances in genetic testing and imaging have led to improved diagnostic capabilities and earlier treatment. Treatment regimens have advanced as well, with newer targeted therapies. Given the rarity of these conditions, however, more research is needed to better understand disease pathology and optimize treatment.

Original language	English (US)
Title of host publication	Encyclopedia of Respiratory Medicine, Second Edition
Publisher	Elsevier
Pages	244-262
Number of pages	19
Volume	6
ISBN (Electronic)	9780081027240
ISBN (Print)	9780081027233
DOIs	https://doi.org/10.1016/B978-0-08-102723-3.00141-4
State	Published - Jan 1 2021
Externally published	Yes

Keywords

Bronchiolitis obliterans
Children’s interstitial lung disease
Diffuse lung disease
Hypoxemia
Immune-related lung disease
Immunodeficiency
Interstitial lung disease
Pulmonary hemorrhage
Pulmonary vasculitis
Rheumatologic lung disease

ASJC Scopus subject areas

General Medicine

Access to Document

10.1016/B978-0-08-102723-3.00141-4

Cite this

@inbook{129fb30c235044e3813665fd2b5565e3,

title = "Diffuse Parenchymal Lung Disease in Later Childhood",

abstract = "Diffuse lung disease (DLD) refers to a heterogenous group of diseases that result in disordered gas exchange. The etiology of DLD in children aged 2–18years old is broad and is most frequently secondary to infectious or post-infectious processes, systemic disease, or immune dysfunction. Advances in genetic testing and imaging have led to improved diagnostic capabilities and earlier treatment. Treatment regimens have advanced as well, with newer targeted therapies. Given the rarity of these conditions, however, more research is needed to better understand disease pathology and optimize treatment.",

keywords = "Bronchiolitis obliterans, Children{\textquoteright}s interstitial lung disease, Diffuse lung disease, Hypoxemia, Immune-related lung disease, Immunodeficiency, Interstitial lung disease, Pulmonary hemorrhage, Pulmonary vasculitis, Rheumatologic lung disease",

author = "Bradford, {Lauren E.} and Wu, {Eveline Y.} and Askin, {Frederic B.} and Vece, {Timothy J.}",

year = "2021",

month = jan,

day = "1",

doi = "10.1016/B978-0-08-102723-3.00141-4",

language = "English (US)",

isbn = "9780081027233",

volume = "6",

pages = "244--262",

booktitle = "Encyclopedia of Respiratory Medicine, Second Edition",

publisher = "Elsevier",

}

TY - CHAP

T1 - Diffuse Parenchymal Lung Disease in Later Childhood

AU - Bradford, Lauren E.

AU - Wu, Eveline Y.

AU - Askin, Frederic B.

AU - Vece, Timothy J.

PY - 2021/1/1

Y1 - 2021/1/1

N2 - Diffuse lung disease (DLD) refers to a heterogenous group of diseases that result in disordered gas exchange. The etiology of DLD in children aged 2–18years old is broad and is most frequently secondary to infectious or post-infectious processes, systemic disease, or immune dysfunction. Advances in genetic testing and imaging have led to improved diagnostic capabilities and earlier treatment. Treatment regimens have advanced as well, with newer targeted therapies. Given the rarity of these conditions, however, more research is needed to better understand disease pathology and optimize treatment.

AB - Diffuse lung disease (DLD) refers to a heterogenous group of diseases that result in disordered gas exchange. The etiology of DLD in children aged 2–18years old is broad and is most frequently secondary to infectious or post-infectious processes, systemic disease, or immune dysfunction. Advances in genetic testing and imaging have led to improved diagnostic capabilities and earlier treatment. Treatment regimens have advanced as well, with newer targeted therapies. Given the rarity of these conditions, however, more research is needed to better understand disease pathology and optimize treatment.

KW - Bronchiolitis obliterans

KW - Children’s interstitial lung disease

KW - Diffuse lung disease

KW - Hypoxemia

KW - Immune-related lung disease

KW - Immunodeficiency

KW - Interstitial lung disease

KW - Pulmonary hemorrhage

KW - Pulmonary vasculitis

KW - Rheumatologic lung disease

UR - http://www.scopus.com/inward/record.url?scp=85143100896&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85143100896&partnerID=8YFLogxK

U2 - 10.1016/B978-0-08-102723-3.00141-4

DO - 10.1016/B978-0-08-102723-3.00141-4

M3 - Chapter

AN - SCOPUS:85143100896

SN - 9780081027233

VL - 6

SP - 244

EP - 262

BT - Encyclopedia of Respiratory Medicine, Second Edition

PB - Elsevier

ER -

Diffuse Parenchymal Lung Disease in Later Childhood

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this